Kingdon Capital Management, L.L.C. Relmada Therapeutics, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $613 Million
- Q4 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 200,000 shares of RLMD stock, worth $57,999. This represents 0.95% of its overall portfolio holdings.
Number of Shares
200,000Holding current value
$57,999% of portfolio
0.95%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
54Shares Held
8.29MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$377,6230.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$364,4440.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$356,0990.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$166,2610.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$143,5920.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $8.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...